25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology

Tanya B. Dorff, Brock O'Neil, Karen E. Hoffman, Daniel W. Lin, Kevin R. Loughlin, Marc Dall'Era

Research output: Contribution to journalReview articlepeer-review


Major changes in the field of prostate cancer over the last 25 years include the implementation of prostate specific antigen screening and the recognition that BRCA confers hereditary risk of prostate cancer. Quality of life and survivorship have driven risk stratification for localized prostate cancer, facilitated by molecular signatures and leading to increased acceptance of active surveillance as a mainstream treatment option. Advances in technology have improved efficacy and reduced toxicity in both radical prostatectomy and radiation therapy for localized prostate cancer. Improved understanding of the androgen receptor has yielded substantially more effective therapies. Future growth areas include personalized treatment based on genomic and genetic information, theranostics radiopharmaceuticals, and more aggressive treatment of metastatic disease to include focal therapy. Multidisciplinary management between specialized urologists, radiation oncologists, and medical oncologists remains central to maximizing patient outcomes.

Original languageEnglish (US)
Pages (from-to)521-527
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Issue number9
StatePublished - Sep 2021
Externally publishedYes


  • Active surveillance
  • Androgen receptor
  • Chemotherapy
  • Prostate cancer
  • Radiation therapy
  • Radical prostatectomy
  • Robotic surgery
  • Survivorship

ASJC Scopus subject areas

  • Oncology
  • Urology


Dive into the research topics of '25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology'. Together they form a unique fingerprint.

Cite this